Compounds > niacinamide

niacinamide and abt-199

niacinamide has been researched along with abt-199 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Arribas, AJ; Bertoni, F; Cascione, L; Curti, E; Gaudio, E; Priebe, V; Rossi, D; Spriano, F; Stathis, A; Tarantelli, C; Zhang, L; Zucca, E1
Abbott, D; Amaya, M; Becker, MW; Culp-Hill, R; D'Alessandro, A; DeGregori, J; Gamboni, F; Gehrke, S; Gustafson, A; Inguva, A; Jones, CL; Jordan, CT; Krug, A; Minhajuddin, M; Nemkov, T; Pei, S; Pollyea, DA; Reisz, JA; Smith, CA; Stevens, BM; Winters, A; Ye, H1
Majeti, R; Zhang, TY1
Ai, H; Chen, L; Ji, X; Mi, RH; Song, YP; Wei, XD; Yin, QS1

Other Studies

4 other study(ies) available for niacinamide and abt-199

ArticleYear
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica, 2019, Volume: 104, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Humans; Hydrazines; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Niacinamide; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Triazoles; Tumor Cells, Cultured

2019
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
    Cell stem cell, 2020, 11-05, Volume: 27, Issue:5

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Niacinamide; Stem Cells; Sulfonamides

2020
Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML.
    Cell stem cell, 2020, 11-05, Volume: 27, Issue:5

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Niacinamide; Sulfonamides

2020
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022, 11-14, Volume: 43, Issue:11

    Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides

2022